Study Summaries

In vitro fibroblast outgrowth assays and in vivo Achilles transection model demonstrating accelerated tendon healing via FAK-paxillin pathway activation.

Quadriceps transection model comparing systemic vs. local BPC-157 administration, demonstrating equivalent efficacy across routes with key pro-angiogenic findings.

Phase III RCT in HIV lipodystrophy demonstrating -15.2% visceral adipose tissue reduction vs. +5.1% placebo gain over 26 weeks of daily SC administration.

Discovery paper establishing ipamorelin's GH-selective pharmacology — equivalent GH release to GHRP-6 with no ACTH, cortisol, or prolactin elevation; selectivity confirmed in vitro and in vivo.

First-in-human dose escalation showing 2–6 fold GH increase and 1.5–3 fold IGF-1 elevation persisting 6–28 days from a single SC injection; preserves pulsatile GH pattern.

Cysteamine duodenal ulcer, indomethacin lesion, and ethanol gastropathy models showing BPC-157 accelerates healing via NO-signaling pathway; complete healing rate 74% vs. 22% control.

Gene expression analysis showing GHK-Cu modulates 4,000+ human genes including collagen synthesis (up to +96%), MMP-1 suppression (-39%), VEGF upregulation, and decorin-mediated anti-fibrotic remodeling.

Thymosin β4 fragment accelerates diabetic wound closure by 42%, angiogenesis via ILK/Akt/VEGF axis, and reduces post-MI infarct scar area by 35% through cardiac cardiomyocyte survival signaling.

Characterization of MOTS-c as a mitochondria-encoded peptide that activates AMPK via the AICAR pathway, reducing HFD-induced obesity (-48% fat mass) and insulin resistance without affecting food intake.

Phase III RCT in 1,961 adults: 2.4 mg weekly semaglutide achieves -14.9% body weight reduction vs. -2.4% placebo at 68 weeks; 69.1% achieve ≥10% loss. Led to FDA approval of Wegovy.

Phase III RCT in 2,539 adults: tirzepatide 15 mg achieves -20.9% body weight reduction at 72 weeks; 57% lose ≥20%; 91% lose ≥5%. Dual GIP/GLP-1 mechanism surpassing semaglutide.

Phase II RCT in 338 adults: triple GLP-1/GIP/glucagon agonist achieves -22.8% body weight at 48 weeks — the highest pharmacological weight loss result published at time of data collection.

Local IGF-1 infusion independent of systemic GH/IGF-1 axis increases muscle wet weight +33% and fiber CSA +18%; satellite cell count doubles; no serum IGF-1 change confirms paracrine mechanism.

20% maximum lifespan extension in SHR mice, 33% reduction in spontaneous tumor incidence, near-full restoration of nocturnal melatonin amplitude, and telomerase activation in human fibroblasts.

MC4R-mediated central arousal: intranasal PT-141 increases erectile events 8-fold in ED; bremelanotide 1.75 mg SC approved by FDA in 2019 as Vyleesi for HSDD in premenopausal women.

GABA-A potentiation without sedation: Selank produces comparable anxiolytic effects to diazepam with no locomotor impairment; BDNF elevated 2.1× at 2h; IL-6 normalized after stress.

ACTH(4–10) analog induces 2.8× hippocampal BDNF and 2.1× cortical VEGF; reduces ischemic infarct volume 31%; improves Morris Water Maze escape latency 38%; TrkB phosphorylation confirmed.

Delta sleep-inducing nonapeptide: +53% delta-wave power, reduced wakefulness, HPA axis normalization, circadian phase modulation via SCN; paradoxical bidirectional effects reviewed.

G-actin sequestration mechanism (Kd ~0.5 µM), LKKTETQ active core vs. TB-500 comparison, T-cell reconstitution acceleration, NF-κB suppression, and cardiac repair: LVEF 39%→66% with 40× epicardial progenitor activation post-MI.

Comparative analysis of GHRH analogs (CJC-1295, Sermorelin) and GHRPs (Ipamorelin, GHRP-6, GHRP-2) covering receptor classes, GH pulsatility, selectivity profiles, and 5–10× combinatorial synergy mechanism.

Quantitative review of thermal, pH, oxidative, aggregation, and photolytic degradation pathways with stability rate tables, pH optimum data, and sequence-specific vulnerability assessment.

DPP-IV proteolysis, renal filtration thresholds, albumin binding pharmacokinetics, and half-life extension strategies (PEGylation, fatty acid conjugation, DAC, Fc fusion) with comparative half-life table for 10 research peptides.

Lyophilized vs. reconstituted storage conditions, container material comparison, freeze-thaw cycling mechanisms and losses, buffer selection, and concentration-dependent surface adsorption.

Mechanistic detail on deamidation via succinimide intermediate, methionine oxidation products, Asp-Pro hydrolysis hotspot, disulfide scrambling, β-elimination, and aggregation nucleation kinetics.

Stability mechanisms in lyophilized state, residual moisture effects, excipient protection strategies, reconstitution-induced damage, and long-term shelf-life data across storage temperatures.